Get the Stockscreener App
2.92
16.57%
-0.58
Autonomix Medical Inc stock is traded at $2.92, with a volume of 7.99M.
It is down -16.57% in the last 24 hours and down -59.50% over the past month.
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
See More
Previous Close:
$3.50
Open:
$3.45
24h Volume:
7.99M
Relative Volume:
35.70
Market Cap:
$1.59M
Revenue:
-
Net Income/Loss:
$-16.72M
P/E Ratio:
-0.0456
EPS:
-64.0349
Net Cash Flow:
$-12.29M
1W Performance:
-34.38%
1M Performance:
-59.50%
6M Performance:
-70.16%
1Y Performance:
-90.34%
1-Day Range:
$2.9001
$3.73
1-Week Range:
$2.9001
$4.6399
52-Week Range:
$2.9001
$32.55
Autonomix Medical Inc Stock (AMIX) Company Profile
Name
Autonomix Medical Inc
Sector
Industry
Phone
832-277-7816
Address
21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS
Compare AMIX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMIX
Autonomix Medical Inc
|
2.92 | 1.59M | 0 | -16.72M | -12.29M | -64.03 |
ABT
Abbott Laboratories
|
103.06 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.25 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.21 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.25 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.63 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Autonomix Medical Inc Stock (AMIX) Latest News
TradingKey - TradingKey
AMIX|Autonomix Medical Inc|Price:2.900|Chg%:-0.600 - TradingKey
AMIX Drops As Warrant Inducement Raises Dilution Fears - StocksToTrade
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study - marketscreener.com
Autonomix reports preclinical data on renal nerve sensing tech By Investing.com - Investing.com Canada
Autonomix Medical Reports Preclinical Study Shows Neural Sensing Platform Can Detect and Localize Renal Nerve Activity - Quiver Quantitative
In an animal study, Autonomix catheter detected kidney nerve changes - Stock Titan
Autonomix Medical, Inc. (AMIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Autonomix Medical receives patent for nervous system assessment tech - Investing.com
Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform - Yahoo! Finance Canada
Frontier tech research, news & data - MLQ.ai
Autonomix Medical (AMIX) Proxy filing Summary - Quartr
Autonomix Medical (AMIX) Registration filing Summary - Quartr
Autonomix Medical, Inc. Common Stock (NASDAQ: AMIX) Share Price, AMIX Stock News, AMIX Share Price & Updates - Kalkine
Autonomix Medical raises up to $2.6M through warrant inducement - MSN
Autonomix Medical (AMIX) Q2 2026 Earnings: Wider-Than-Expected Loss Highlights Cash Burn for Clinical-Stage Device FirmEarnings Risk Report - dars.gov.et
Autonomix Medical Announces $2.6 Million At-the-Market Warrant Inducement Agreement to Accelerate Growth - Minichart
Autonomix Medical Secures $2.6 Million From Warrant Inducement, Issues New Series D Warrants - TradingView
Autonomix granted U.S. patent for overactive bladder diagnosis - TipRanks
Autonomix Medical receives patent for overactive bladder device - Investing.com UK
Autonomix Medical receives patent for overactive bladder device By Investing.com - Investing.com Nigeria
Autonomix Medical Receives U.S. Patent Expanding Neural Sensing Platform Into Overactive Bladder Urology Market - Moomoo
Autonomix Medical Receives U.S. Patent Expanding Neural Sensing Platform into Overactive Bladder Urology Market - Quiver Quantitative
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform - GlobeNewswire
Autonomix Patent Covers Catheter That Maps and Treats Bladder Nerves - Stock Titan
Investor Agrees to Exercise 428,731 Autonomix Warrants - Stock Titan
Autonomix enters into $2.6M warrant inducement priced at $6.00 - TipRanks
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules - marketscreener.com
Autonomix Medical wins new patent for neural sensing technology - Proactive financial news
symbol__ Stock Quote Price and Forecast - CNN
Autonomix granted Canadian patent for neural sensing - TipRanks
Autonomix Medical Announces Canadian Patent Grant Strengthening Its Real-Time Nerve Sensing and Denervation IP Portfolio - Quiver Quantitative
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant - GlobeNewswire
Autonomix Medical Inc. (AMIX) Slips 12.48% as Shares Test Key Support LevelsDealer Gamma - dars.gov.et
Autonomix Medical Regains Nasdaq Compliance, Preserving Listing Status - The Globe and Mail
Autonomix Medical, Inc. 8-K Filing: NASDAQ Compliance Update and Company Details (July 2026) - Minichart
Autonomix Medical regains Nasdaq compliance after 10-day $1.00 bid-price streak - TradingView
Autonomix Medical (NASDAQ: AMIX) restores Nasdaq minimum bid price compliance - Stock Titan
Autonomix Medical (AMIX) Slips 1.58% as Stock Tests Key Support ZoneElliott Wave Count - dars.gov.et
AMIX Q2 2026 Earnings: Loss Narrows as Clinical Progress Offsets Cautious OutlookShare Repurchase Impact - DonanımHaber
AMIXAutonomix Medical Inc Options - Finviz
Autonomix Medical (AMIX) Surges 13% as Bulls Test Key Resistance at $7.25Short Setup Alerts - dars.gov.et
Autonomix Medical Inc. (AMIX) Q1 2026 Earnings: Narrower-than-Expected Loss as Pre-Revenue Company Advances R&DBuyback Announcement Report - dars.gov.et
AMIX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Stock Amid Continued Pre-Revenue Stage - DonanımHaber
AMIX Q1 2026 Earnings: Narrower Loss Surprise Fails to Lift Shares as Pre-Revenue Progress Remains in Focus - dars.gov.et
Enterprise value to EBIT forward of Autonomix Medical, Inc. – NASDAQ:AMIX - TradingView
Price to book forward of Autonomix Medical, Inc. – NASDAQ:AMIX - TradingView
Autonomix Medical Enacts 1-for-21 Reverse Stock Split - TipRanks
Autonomix Medical (AMIX) consolidates shares in 1-for-21 reverse stock split - Stock Titan
Autonomix Medical Inc (AMIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Autonomix Medical Announces Standalone Neural Sensing Platform with Evidence of Real-Time Renal Nerve Activity - marketscreener.com
Autonomix Medical Inc Stock (AMIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
2.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):